Candel Therapeutics announced positive results from their phase 3 clinical trial of CAN-2409 for prostate cancer, showing a significant 30% reduction in recurrence risk. This announcement was made on May 22, 2025, ahead of its presentation at the ASCO Annual Meeting from May 30 to June 3, 2025.